Published in Br J Cancer on May 01, 1989
Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax (2005) 1.35
Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer (1996) 0.97
Epidermal growth factor receptor in lung malignancies. Comparison between cancer and normal tissue. Br J Cancer (1991) 0.95
Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Br J Cancer (1995) 0.95
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer (1990) 0.93
Growth control by epidermal growth factor and transforming growth factor-alpha in human lung squamous carcinoma cells. Br J Cancer (1992) 0.81
Tyrosine phosphorylation of 100-130 kDa proteins in lung cancer correlates with poor prognosis. Br J Cancer (1996) 0.81
A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells. Ann Thorac Cardiovasc Surg (2009) 0.78
Missense Mutations in Exons 18-24 of EGFR in Hepatocellular Carcinoma Tissues. Biomed Res Int (2015) 0.75
Phosphorylated tyrosine-containing proteins in primary lung cancer correlates with proliferation and prognosis. Br J Cancer (2002) 0.75
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature (1984) 14.21
Epidermal growth factor. Annu Rev Biochem (1979) 11.82
Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem (1962) 9.87
Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet (1987) 4.28
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76
Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res (1986) 2.38
Transforming growth factor(s) production enables cells to grow in the absence of serum: an autocrine system. Proc Natl Acad Sci U S A (1982) 2.27
Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest (1984) 2.15
Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol (1986) 2.02
Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer (1987) 1.83
Cellular localisation of human epidermal growth factor receptor. Cell Biol Int Rep (1984) 1.77
Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res (1986) 1.60
Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels. Cancer Res (1984) 1.45
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer (1986) 1.45
Epidermal growth factor receptors in lung tumours. J Pathol (1987) 1.36
Epidermal growth factor, its receptor, and related proteins. Exp Cell Res (1986) 1.27
Mechanism of growth arrest of chemically transformed cells in culture. Cancer Res (1978) 1.21
Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst (1987) 1.08
Growth of mammary epithelial cells in breast-cancer biopsies correlates with EGF binding. Int J Cancer (1987) 0.81
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol (1990) 5.90
The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. Br J Cancer (1983) 4.33
Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci (1992) 3.18
Childhood leukaemia in North West England 1954-1977: epidemiology, incidence and survival. Br J Cancer (1981) 2.97
To clot or not to clot? That is the question in central venous catheters. Clin Radiol (2004) 2.85
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71
Conducting clinical research in the new NHS: the model of cancer. United Kingdom Coordinating Committee on Cancer Research. BMJ (1994) 2.70
Hypertensive pulmonary vascular disease in states of chronic hypoxia. J Pathol Bacteriol (1968) 2.61
Discrepancies between clinical and autopsy diagnosis and the value of post mortem histology; a meta-analysis and review. Histopathology (2005) 2.52
Reproductive and neonatal losses associated with possible encephalomyocarditis virus infection in pigs. Vet Rec (1990) 2.52
Alternate splicing produces a novel cyclin D1 transcript. Oncogene (1995) 2.48
Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax (2004) 2.45
Incidence of malignant disease in childhood: a 24-year review of the Manchester Children's Tumour Registry data. Br J Cancer (1980) 2.40
Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol (2000) 2.35
Mesotheliomas with deciduoid morphology: a morphologic spectrum and a variant not confined to young females. Am J Surg Pathol (2000) 2.33
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer (2000) 2.30
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18
Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.17
Concomitant methotrexate and radiotherapy in advanced head and neck cancer: 15-year follow-up of a randomized clinical trial. Clin Oncol (R Coll Radiol) (2001) 2.16
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer (2009) 2.13
Treatment of mediastinitis: early modified Robicsek closure and pectoralis major advancement flaps. Ann Thorac Surg (1998) 2.10
Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax (1995) 2.04
Expression of the ERBB3 gene product in breast cancer. Br J Cancer (1992) 2.01
Is the cold chain for vaccines maintained in general practice? BMJ (1993) 2.00
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer (1987) 1.97
Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res (1995) 1.96
Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol (1990) 1.94
Genetic predisposition to human lung cancer. Br J Cancer (1986) 1.94
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol (2011) 1.88
High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A (1997) 1.81
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1994) 1.79
Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology (2006) 1.77
Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours. Br J Cancer (2008) 1.74
The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (1999) 1.71
Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med (1990) 1.70
Volunteers or victims: patients' views of randomised cancer clinical trials. Br J Cancer (1995) 1.70
Excess risk of breast cancer in the mothers of children with soft tissue sarcomas. Br J Cancer (1984) 1.70
Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene (1990) 1.69
Incidence of synchronous and metachronous colorectal carcinoma. Br J Surg (1984) 1.68
c-Ki-ras amplification in human lung cancer. Br J Cancer (1986) 1.67
Busulphan lung. Thorax (1969) 1.63
Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res (2000) 1.63
Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol (2000) 1.62
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol (2003) 1.62
The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas. Int J Cancer (1984) 1.61
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol (1995) 1.61
Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood (1993) 1.56
Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet (1984) 1.56
Estimation of renal function -- what is appropriate in cancer patients? Clin Oncol (R Coll Radiol) (2008) 1.55
Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Clin Oncol (R Coll Radiol) (2013) 1.54
Two methods for measurement of oestradiol-17 beta and progesterone receptors in human breast cancer and correlation with response treatment. Eur J Cancer (1977) 1.52
Multiple tissue core arrays in histopathology research: a validation study. J Pathol (2000) 1.51
An assessment of clinically optimal gold marker length and diameter for pelvic radiotherapy verification using an amorphous silicon flat panel electronic portal imaging device. Br J Radiol (2005) 1.50
Intracellular trafficking and killing of Streptococcus pneumoniae by human alveolar macrophages are influenced by opsonins. Infect Immun (2000) 1.48
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions. Eur Respir J (1990) 1.46
Effect of oxygen on the lungs after blast injury and burns. J Clin Pathol (1981) 1.46
Lead toxicosis in mallard ducks. Wildl Dis (1968) 1.46
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer (1986) 1.45
Steroid receptors in human meningioma. Clin Neuropharmacol (1984) 1.45
The value of hyoscine butylbromide in pelvic MRI. Clin Radiol (2007) 1.43
Pathologic changes in edema disease of swine. Am J Vet Res (1969) 1.43
Improving prospects for employment of the haemophiliac. Br Med J (1980) 1.43
Staging of advanced cervical carcinoma using MRI-predictors of outcome after radical radiotherapy. Clin Radiol (2003) 1.42
Acute lymphoid leukaemia of childhood in North-West England. Lancet (1979) 1.41
Carcinosarcoma of the ovary. Br J Cancer (2003) 1.41
Should cryptogenic organizing pneumonia be included in the classification of pulmonary allograft rejection? J Heart Lung Transplant (1996) 1.41
Preoperative radiotherapy for operable rectal cancer--is a lower dose to a reduced volume acceptable? Clin Oncol (R Coll Radiol) (2006) 1.39
Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol (2006) 1.39
The Christie Hospital breast conservation trial: an update at 8 years from inception. Clin Oncol (R Coll Radiol) (1993) 1.39
A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer (1993) 1.38
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer (1996) 1.38
Right ventricular hypertrophy in emphysema. J Pathol (1972) 1.38
Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer (1994) 1.37
O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res (1991) 1.34
Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer (1992) 1.34
Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst (2000) 1.33
Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res (1989) 1.31
Feline mammary hypertrophy/fibroadenoma complex: clinical and hormonal aspects. Am J Vet Res (1981) 1.30
Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax (2004) 1.29
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer (1998) 1.29
Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. Bone Marrow Transplant (2003) 1.28
Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. Oncogene (1998) 1.28
ACTH precursors characterize the ectopic ACTH syndrome. Clin Endocrinol (Oxf) (1994) 1.27
Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer (1998) 1.27
Measurement of oestradiol receptors by five institutions on common tissue samples. Br J Cancer (1978) 1.26
The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br J Cancer (1985) 1.26
KiS1--a novel monoclonal antibody which recognizes proliferating cells: evaluation of its relationship to prognosis in mammary carcinoma. J Pathol (1992) 1.23
Squamous carcinoma of the breast. J Clin Pathol (1978) 1.23